AngioDynamics (ANGO) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
AngioDynamics Reports Fiscal 2018 Third Quarter Financial Results
March 29, 2018 7:00 AM EDTFiscal 2018 Third Quarter Highlights
Net sales of $83.9 million, a decrease of 2.0% year over year Gross margin expanded 300 basis points year over year to 54.2% GAAP EPS of $0.37; Adjusted EPS of $0.25 per share Announced the launch of a wireless ultrasound device FDA granted Breakthrough designation to NanoKnife® System for the treatment of Stage III pancreatic cancer
LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of... More
